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Background: The proportion of strokes occurring in younger adults has been rising over the past decade. Due
to the far longer life expectancy in the young, stroke in this group has an even larger socio-economic impact.
However, information on etiology and prognosis remains scarce.
Methods/design: ODYSSEY is a multicentre prospective cohort study on the prognosis and risk factors of patients
with a first-ever TIA, ischemic stroke or intracerebral hemorrhage aged 18 to 49 years. Our aim is to include 1500
patients. Primary outcome will be all cause mortality and risk of recurrent vascular events. Secondary outcome will
be the risk of post-stroke epilepsy and cognitive impairment. Patients will complete structured questionnaires on
outcome measures and risk factors. Both well-documented and less well-documented risk factors and potentially
acute trigger factors will be investigated. Patients will be followed every 6 months for at least 3 years. In addition,
an extensive neuropsychological assessment will be administered both at baseline and 1 year after the stroke/
TIA. Furthermore we will include 250 stroke-free controls, who will complete baseline assessment and one
neuropsychological assessment.
Discussion: ODYSSEY is designed to prospectively determine prognosis after a young stroke and get more insight
into etiology of patients with a TIA, ischemic stroke and intracerebral hemorrhage in patients aged 18 to 49 years old
in a large sample size.
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Recent studies have shown that the proportion of strokes
occurring in adults younger than 50 years of age has
increased from 13 to 19% over the past decade [1,2]. Due
to the longer life expectancy in the young compared with
a general elderly stroke patient, stroke in this younger
group has a large impact on number of years lost to
ill-health, disability or early death [3]. This impact will
not only be determined by the direct mortality and residual
post-stroke deficit, but may also be influenced by future* Correspondence: Frankerik.deleeuw@radboudumc.nl
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reproduction in any medium, provided the orvascular events, cognitive impairment or post-stroke epi-
lepsy that may occur throughout their post-stroke lives
[4,5]. Especially for young patients reliable information
on this prognosis is of great importance as their stroke
occurs in the period of life in which they would like to
form families, have an active social life and make decisive
career moves. However, it is exactly the prognosis of this
younger group that remains unclear.
Previous studies on stroke in the young were mainly
retrospective and included patients who had their index
events at times with a completely different secondary
prevention strategy. Most studies only aimed at prognosis
in terms of mortality and vascular events, which are very
important outcome measures. However, other important
post-stroke complications, such as cognitive deficits, post-td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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into account. Furthermore previous studies have only
included patients with an ischemic stroke, whereas studies
in younger patients with a transient ischemic attack (TIA)
or intracerebral hemorrhage are scarce. There is growing
evidence that despite the fact that TIA patients suffer
from (by definition) transient neurological deficits, their
cognitive or social sequelae may last way longer [6-8].
In addition, survival of patients with an intracerebral
hemorrhage has improved substantially due to improved
care resulting in longer post-stroke life expectancy. Infor-
mation on prognosis after an intracerebral hemorrhage or
TIA is consequently of great importance as well, both for
patients and their health professionals when counselling
their patients with information on the course of the disease.
Apart from uncertainties about prognosis and the
major socio-economic impact of a young stroke, the
explanation for the increased incidence of young stroke
remains unclear. It has been suggested that an increased
prevalence in traditional vascular risk factors, such as
diabetes mellitus and obesity due to unhealthy life style
and poor education, results in (more) atherosclerosis
already at younger ages which may lead to stroke [9,10].
Furthermore, a rising incidence of substance abuse which
may be more pronounced in the young might play a role
[11]. However, despite the use of ever increasing additional
clinical investigations that take place in renowned special-
ized stroke centers, etiology remains unknown in more
than 30% of the young stroke patients [12]. An approach
to get more insight into pathophysiological mechanisms
of a young stroke, is to identify potentially acute trigger
factors that precede a young stroke. In studies on sub-
arachnoid hemorrhage and ischemic stroke in elderly,
several acute trigger factors already have been identified
(including for example vigorous physical exercise, emo-
tions and coffee consumption) [13,14].
The assessment of prognosis and etiology is a first step
in informing young stroke patients in terms of prognosis.
We therefore will perform the Observational Dutch Young
Symptomatic StrokE studY (ODYSSEY); a large multi-
centre prospective cohort study on prognosis and both
traditional and other risk factors of patients with a TIA,
ischemic stroke or intracerebral hemorrhage aged 18
through 49 years.
Methods/design
Study design
ODYSSEY is a multicentre prospective cohort study that
investigates prognosis and risk factors of patients with
a TIA, ischemic stroke or intracerebral hemorrhage
aged 18 through 49 years. Within this setting we will
perform a case-crossover design on potential acute trigger
factors. The Medical Review Ethics Committee region
Arnhem-Nijmegen approved the study (NL41531.091.12)and all participants will be requested to sign an informed
consent form.
Objectives
The main objective of our study is to determine the risk
of mortality and recurrent vascular events in patients with
a first-ever young TIA, ischemic stroke or intracerebral
hemorrhage.
Secondary objectives are to determine the risk of post-
stroke epilepsy, cognitive impairment and (vascular)
dementia after a young stroke. The influence of a young
stroke on functional outcome, quality of life and depressive
symptoms will also be investigated. We will investigate
the prevalence of traditional vascular risk factors and
the relation between potential acute trigger factors and
the occurrence of a young stroke. In addition we will
identify baseline characteristics that are associated with
our primary and secondary outcomes.
Study population
Patients
All consecutive patients with an acute first-ever young
stroke or TIA admitted to the stroke unit or outpatient
department of one of the participating centers will be
asked to participate in the study. Participating study centers
are the Departments of Neurology at the Haga Hospital
Den Haag, St Franciscus Gasthuis Rotterdam, Tweesteden
Hospital and St. Elisabeth Hospital Tilburg, Catharina
Hospital Eindhoven, Amphia Hospital Breda, Medisch
Spectrum Twente Enschede, Canisius Wilhelmina Hospital
Nijmegen, Rijnstate Hospital Arnhem and Radboud
University Medical Centre Nijmegen.
The following Inclusion criteria will be applied:
1. First-ever acute stroke (ischemic stroke or
intracerebral hemorrhage) or TIA with
corresponding lesion and/or evidence of acute
arterial occlusion on CT (A)- or MRI/A-scan.
2. Age 18 through 49 years.
3. Onset of symptoms within 14 days prior to inclusion.
TIA is defined as a rapidly evolving focal neurological
deficit, without positive phenomena such as twitches, jerks
or myoclonus, with no other than vascular cause lasting
less than 24 hours. Acute stroke is defined similar, but
with symptoms persisting for more than 24 hours. On the
basis of neuro-imaging stroke is further divided into intra-
cerebral hemorrhage and ischemic stroke. Hemorrhagic
transformation of an ischemic stroke will be classified as
an ischemic stroke.
Exclusion criteria
1. History of a TIA or stroke.
2. Traumatic intracerebral hemorrhage.
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4. Intracerebral hemorrhage due to a known ruptured
aneurysm.
5. Intracerebral hemorrhage in a known cerebral
malignancy (either primary brain tumor or metastasis).
6. Transient monocular blindness or retinal infarction.
7. Cerebral venous sinus thrombosis.
8. Not permanently living in the Netherlands.
Controls
Controls will be recruited among patients’ spouses, rela-
tives or social environment. Controls have to be aged 18
through 49 years and will be matched for mean age, sex
and level of education. A history of TIA, ischemic stroke
or intracerebral hemorrhage is an exclusion criterion,
which will be confirmed by a validated questionnaire for
verifying stroke-free status [15].
Procedures
All eligible patients will be recruited during the evaluation
of their TIA or stroke. Patient recruitment is planned over
a 3-to-4 year period and we intend to include 1500
patients. After informed consent and written approval
of the participants patients will formally enter the study. If
the patient is unable to provide informed consent, consent
is provided by the patient’s legally acceptable representative.
During admission or visit to the outpatient department,
patients will undergo a baseline assessment. In addition,
patients will undergo an extensive baseline neuropsycho-
logical investigation 6–8 weeks after the index event. The
same neuropsychological assessment will be administered
1 year after the TIA or stroke. After baseline assessment,
patients will be followed every 6 months for at least 3 years
by telephone interview. See Figure 1 for the flowchart
of the study design. In addition we intend to include 250
controls who will undergo a baseline assessment on demo-
graphics and a neuropsychological assessment.Figure 1 Study design.Sample size and power calculation
Sample size is based on the least frequent endpoint after
young stroke. According to previous literature cumulative
incidence of post-stroke dementia is approximately 1% per
year. To adjust for the most important confounders (age,
sex, stroke severity, education and depression) in our cox
proportional hazard analysis, at least 40 cases are needed.
To detect a cumulative incidence of 1% per year and a
follow-up of 3 years with a power of 80%, results in a
sample size of at least 1500 patients.
Control subjects are included to compare cognitive tasks
between patients and healthy subjects. Our pilot studies
showed that ‘attention’ is the cognitive task which differs
the least between patients and healthy subjects (impaired
in 14% versus 8% respectively). To identify this difference
with a power of 80% and alpha 0.05 in previous mentioned
1500 patients, 265 healthy control subjects need to be
included.
Measures-baseline
Medical history
At baseline all participants (patients and controls) will
undergo standardized structured questionnaires on demo-
graphics, level of education (scored using seven categories
in accordance with the Dutch educational system: 1 = less
than primary school; 7 = university degree) [16], marital
status and employment.
The presence of cardiovascular risk factors will be
assessed by standardized, structured questionnaires and
classified according to the current guidelines of the
American Heart Association [17]. Non-modifiable risk
factors include age, sex and a family history of cardio-
vascular diseases in the next of kin. Well-documented
and potentially modifiable risk factors will include cardio-
vascular diseases (valvular heart diseases, myocardial infarc-
tion, coronary artery bypass grafting (CABG), percutaneous
transluminal coronary angioplasty (PTCA) and peripheral
Table 1 Hazard period for potential trigger factors
Hazard time
Smoking 1 hour
Alcohol consumption 24 hours
Recreational drugs 4 hours
Consumption of coffee 1 hour
Consumption of cola 1 hour
Valsalva maneuver 1 hour
Fever 24 hours
Positive and negative emotions 1 hour
Anger 1 hour
Physical exercise 1 hour
Sexual activity 2 hours
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mented potential modifiable risk factors will included
diabetes mellitus, hypertension, dyslipidemia, smoking
and atrial fibrillation.
Less-well documented, potentially modifiable risk factors
included a history of migraine, acute infections, the use
of oral contraceptives, alcohol consumption and the use of
recreational drugs. Patients will be screened for migraine
with the MISS questionnaire, a screening instrument regu-
larly used in Dutch hospitals containing questions about
migraine in terms of diagnosis, frequency, aura and con-
comitant symptoms. Definitions of both well-documented
and less-well documented, potentially modifiable risk
factors are shown in Additional file 1.
In addition to the assessment of risk factors, patients
will be asked about a history of epilepsy, pregnancies and
complications, pulmonary embolism, deep vein throm-
bosis and current medication use. Furthermore functional
performance prior to the index event will be assessed by
modified Rankin scale.
Potential trigger factors
In addition to the questionnaires on cardiovascular risk
factors, patients will be requested to fill out a standardized
structured self-reported questionnaire on acute factors
that might trigger stroke. For each trigger factor, patients
will be asked to report their usual exposure during the
past year and the exposure during a predefined period
before the onset of stroke; the hazard period. Hazard
periods are based on the estimated duration of the effect
of each potential trigger factor as used in previous studies
investigating trigger factors of cardiovascular events
[13,14,18]. In addition to exposure in the hazard period,
patients will be asked about the last exposure before
stroke. In this case-crossover design, each patient will
serve as his or her own control [19].
Potential trigger factors that will be investigated include
smoking, consumption of alcohol, recreational drugs
(cocaine, heroin, methadone, amphetamine, cannabis,
XTC, anabolic steroids, hallucinogens and EPO), caffeine
containing drinks (coffee and cola), valsalva maneuver,
fever, positive and negative emotions, physical exercise
and sexual activity. Table 1 shows the hazard periods
for the different potential trigger factors. To investigate
the effect of valsalva maneuver as stroke trigger, patients
will be asked about sneezing, coughing, nose-blowing
and heavy lifting. The exposure to positive and negative
emotions will be measured using the PANAS scale, a 5
level scale which contains 9 positive and 9 negative affects
[20]. Whenever patients report a mean score of ≥3.5
on the negative affects, they will be considered exposed
to negative emotions [21]. Anger will be measured using
the anger scale, consisting of 7 levels of anger [22]. Patients
are considered exposed to anger if they report a peak levelof anger ≥4 (very angry, furious or enraged). Physical exer-
cise will be expressed in the metabolic equivalent value
(MET) according to accepted standards [23]. The exposure
of vigorous to extreme exercise (MET ≥ 6) will be reported
[18]. Consumption of alcohol, recreational drugs, coffee,
cola and smoking will be reported in units per day.
Clinical evaluations
Physical examination and additional investigations
Baseline standard clinical evaluation will be performed
during admission or visit to the outpatient departments.
Clinical signs, symptoms and duration of stroke and TIA
will be reported. Stroke severity will be assessed by the
National Institutes of Health Stroke Scale (NIHSS) [24]
and modified Rankin scale (mRS) [25], both measured at
admission and at discharge.
Furthermore standard clinical evaluation will include a
physical examination and laboratory measures. Additional
file 2: Table S1 shows an overview of all investigations.
Additional investigational DNA will be stored for future
genetic analysis. Patients must consent for storage of the
DNA and future analysis.
Classification of TIA or stroke: etiology and neuro-imaging
Etiology of ischemic stroke and TIA will be classified
according to the TOAST criteria [26], Causative Classifica-
tion System of ischemic stroke (CCS) [27] and ASCO [28].
Etiology of intracerebral hemorrhage will be classified
as hypertensive (deep or infratentorial hemorrhage in
combination with hypertension), arteriovenous malfor-
mation, cavernous angioma, coagulopathy (iatrogenic or
bleeding disorder), central nervous system infection,
septic embolism, vasculitis, substance abuse or unknown
(cryptogenic, multiple causes and incomplete evaluation)
[29]. Etiology will be based on neuro-imaging, medical
history and the use of medication.
All patients will undergo neuro-imaging and additionally
CT-angiography, MR-angiography or ultrasound will be
Table 2 Neuropsychological assessment
Domain Test/questionnaire
Cognitive assessment
Global cognitive
functioning
Mini mental state examination
Episodic memory Rey auditory verbal learning test
Speed of information
processing
Stroop color word test
Letter-digit substitution task
Visuoconstruction Rey complex figure test - copy
Executive functioning Animal fluency test
Stroop interference score
Brixton spatial anticipation test
Neglect Star cancellation
Language deficits Short token test
Attention and
working memory
Digit span test
Paper and pencil memory
scanning task
Subjective cognitive
complaints
Cognitive failures questionnaire
Mood and functional outcome
History of depression
Anxiety and depression Mini international neuropsychiatric
interview
Fatigue Checklist on individual strength (CIS20r)
Quality of life EQ-5D
Health status Stroke impact scale
SF-12
Functional outcome Modified rankin score
Barthel index
Instrumental activities of daily living
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MRI-scans will be reviewed centrally in the Radboud
University Medical Centre. TIA and ischemic strokes will
be classified according to arterial territory and addition
will be classified as lacunar or territorial. Whenever hemor-
rhagic transformation of an ischemic stroke has occurred
this will be documented.
Intracerebral hemorrhage will be classified as infratentor-
ial (brainstem or cerebellar) or supratentorial hemorrhage
(lobar, deep or ventricular) with or without ventricular
involvement. Lobar hemorrhage will be further subdivided
into frontal, temporal, parietal or occipital. In addition
hematoma volume will be calculated according to the
A*B*C/2 method [30].
Course of the disease
Furthermore the course of the disease during admission
will be reported, including medication use, (intra-venous
or arterial) thrombolysis or other treatments and compli-
cations. Whenever a patient develops a recurrent vascular
event (ischemic stroke, intracerebral hemorrhage, TIA,
myocardial infarction) or post-stroke epilepsy this will
be reported. In addition the course of stroke severity
during admission will be assessed by mRS and NIHSS.
Measures - follow up
All patients will be followed every 6 months by telephone
interview. Patients will undergo standardized structured
questionnaires on the occurrence of post-stroke epilepsy
and recurrent vascular events (TIA, ischemic stroke, intra-
cerebral hemorrhage, myocardial infarction, CABG, PTCA
and other revascularization procedures). In addition they
will be asked about well-documented potentially modifi-
able vascular risk factors (diabetes mellitus, hypertension,
dyslipidemia and smoking), the use of medication and
pregnancies. In case a patient has died, this information
will be retrieved from the general practitioner.
As measure of functional outcome mRS and Barthel
Index [31] will be administered and patients will be asked
about their occupation or education. Occupation will be
categorized into 4 skills levels (ranging from first = primary
education only to fourth = tertiary education with university
degree or equivalent), according to the ISCO-88 (Inter-
national Standard Classification of Occupations) [32].
Neuropsychological investigation
An extensive neuropsychological investigation will be
administered in all patients six weeks and 1 year after
the index event (using parallel versions for some tests
that are susceptible to test-retest effects). Controls will
be assessed only once at baseline.
The cognitive assessment includes tests used in other
large scale epidemiologic studies covering the main cog-
nitive domains [33,34]. Table 2 shows an overview of allcognitive tests performed. Global cognitive functioning
will be assessed by the Mini Mental State Examination
[35]. Episodic memory will be measured using the 3-trial
version of the Rey Auditory Verbal Learning Test [36],
which includes a delayed recall and a delayed recognition
trial, assessing the acquisition and retention of new verbal
information. To assess speed of information processing,
Parts I and II of the Stroop Color Word test [37] and
the Letter-Digit Substitution Task (an adaptation of the
Digit-Symbol Substitution Test [38]) will be used. Visuo-
constructive ability will be assessed by the copy trial of the
Rey Complex Figure Test [39]. With respect to executive
functioning, verbal fluency (animal naming, 60 sec) will be
used to test response regeneration, the Brixton Spatial
Addition Task [40] will be administered as a measure
of concept shifting and rule detection, and the Stroop
Interference Score [32] will be included as a measure of
response inhibition. Furthermore participants will complete
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short screening battery to assess the presence of a visual
neglect [41]. Participants will be tested for language deficits
by means of the short version of the Token Test, validated
for the Dutch language [42]. To evaluate attention and
working memory we will assess the Digit Span subtest
from the Wechsler Adult Intelligence Scale - Fourt Edition
[43] and the Paper and Pencil Memory Scanning Task
(4 subtasks) [44]. Subjective cognitive complaints will
be assessed by the Cognitive Failure Questionnaire [45].
The cognitive assessment will be performed in quiet rooms
and administered by trained investigators.
In case cognitive impairment is suspected on the basis
of the cognitive screening, relatives will be interviewed on
the influence of cognitive performance on daily functioning
by means of the IQCODE [46].
In addition to the cognitive screening, questionnaires
on mood and functional outcome will be administered.
Participants will be screened for a history of depressive
symptoms with a standardized questionnaire used in pre-
vious large-scale epidemiological studies [47], in which
normal reactions to stressful events or normal grief will
be excluded. A history of depression is defined as those
episodes that require attention of a medical caregiver,
including both minor depression and major depressive
syndromes as defined by the Research Diagnostic Criteria
[48]. Current anxiety and depression will be evaluated
by means of the Mini International Neuropsychiatric
Interview [49], which is a short diagnostic structured
interview based on the DSM-IV. Functional outcome
will be assessed by mRS, Barthel Index and Instrumental
Activities of Daily Living [50].
Furthermore participants will fill out validated self-report
questionnaires on fatigue by means of the Checklist on
Individual Strength (CIS20r) [51] and quality of life by
means of the EQ-5D [52]. Health status will be assessed
by means of the Stroke Impact Scale [53] and SF-12 [54].
Outcome
Primary outcome will be all cause mortality. Depending
on date and location of death information on cause of
death will be available either from the hospital (in-hospital
mortality) or the general practitioner. Secondary measures
of outcome will be the composite endpoint of any recur-
rent vascular event. Vascular events will include TIA, fatal
or non-fatal stroke (ischemic or hemorrhagic), myocardial
infarction, CABG, PTCA and other revascularization
procedures, whichever occurs first. Stroke and TIA will be
defined similar as the index event. Myocardial infarction
will be defined by ischemic symptoms with electrocar-
diographic, cardiac biomarker, or pathological evidence
of infarction according to the universal definition of
myocardial infarction [55].In addition, the occurrence of post-stroke epilepsy and
dementia will be noted as secondary outcome. Epilepsy
will be classified and defined according to the International
League Against Epilepsy, in which patients with a single
seizure associated with an enduring condition that could
cause epilepsy, meet the criteria of epilepsy [56,57]. Demen-
tia will be defined according to DSM-5. Finally, tertiary
outcome measures will include functional outcome, qual-
ity of life and mood disorders.
Whenever an outcome event is suspected with the
aid of standardized structured questionnaires, informa-
tion from the treating physician will be retrieved. This
information will be verified and adjudicated by two
independent experienced neurologists or, in case of a
myocardial infarction, by a cardiologist, who will be
blinded for the index event.
Analysis
Cumulative risk of mortality, vascular events and epilepsy
will be estimated by Kaplan-Meier survival analysis. In
the analysis for epilepsy and vascular events, patients
who have died will be censored. Cox proportional hazard
analysis will be used to calculate hazard ratios for previous
mentioned primary and secondary outcome measures
adjusted for the necessary covariates. For the outcome
measures vascular events and epilepsy, additional com-
peting risk analysis will be performed in which death
will be considered as a competing risk as suggested by
Fine and Gray [58,59].
For the analysis containing cognition, raw test scores
of each test will be calculated and converted to Z-scores
using the mean and standard deviation of the controls.
Z-scores of tests assigned to the same cognitive domain
will be averaged and used in all subsequent analyses as
composite Z-score, or domain score. ANCOVA models
will be used to compare means of different variables on
each cognitive domain adjusted for the necessary covari-
ates. Linear regression will be used to explore the effect of
different variables on each cognitive domain and results
will be reported as beta coefficients.
For the analysis including acute trigger factors, a case-
crossover design as previous described will be used in
which each patient will serve as his or her own control
[19]. The ratio of the observed exposure frequency in
the hazard period to the expected frequency based on
the control period will be used to estimate relative risks.
Hazards ratios, beta coefficients and relative risks will be
calculated with their corresponding 95% confidence inter-
vals. Comparisons of continuous variables will be done by
Student’s t test or analysis of variance or, in case of skewed
distributions which cannot be normalized, corresponding
nonparametric tests will be used. Chi-squared test will be
used for comparison of categorical variables.
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ODYSSEY aims to investigate the prognosis after a first-
ever young TIA, ischemic stroke or intracerebral hemor-
rhage in terms of mortality, recurrent vascular events,
post-stroke epilepsy and cognitive impairment. Further-
more we intend to determine the prevalence of vascular
risk factors in young stroke patients and to relate potential
acute trigger factors to the occurrence of a young stroke.
Strong elements of the study are the multicentre pro-
spective design with multiple follow-up assessments. Due
to the multicentre approach we will be able to include a
large sample size, covering a vast part of the Netherlands
including both academic and regional hospitals. The pro-
spective design allows us to obtain an accurate evaluation
of the prognosis of young stroke patients, unlike previous
small retrospective studies. Furthermore, most previous
studies only included patients with an ischemic stroke
while we will include patients with a TIA and intracerebral
hemorrhage as well. This allows us to study a large part of
the spectrum of stroke in young adults. Since patients
will only be eligible for inclusion in our study when
they have positive brain imaging corresponding with
their neurological deficits, ODYSSEY will have a clearly
defined population without misclassification. In retro-
spective studies often a clinical diagnosis was used for
defining stroke, leading to a more heterogeneous study
population.
Only few small studies among young stroke patients
investigated cognitive performance after a young stroke.
To our knowledge we are the first to investigate cogni-
tive performance both at baseline as well as 1 year after
follow-up. This enables us to describe the course of cog-
nitive performance and potential further decline after an
initial assessment. On top of this we will include healthy
matched control subjects which will allow for a comparison
of cognitive performance with a healthy group.
In addition, this study is the first investigating poten-
tial acute trigger factors preceding a stroke or TIA in a
non-selected young population. In studies on subarachnoid
hemorrhage and ischemic stroke in the elderly, several
acute trigger factors already have been identified [13,14].
Due to the case-crossover design we hope to identify
possible acute trigger factors, which may give us more
insight in the underlying pathophysiological mechanisms
of a young stroke. As some of those trigger factors are
potentially modifiable, the assessment of acute trigger
factors might lead to new prevention strategies in high
risk patients.
The estimation of etiology and prognosis is a first step
in informing young stroke patients in terms of prognosis.
The estimates of recurrent vascular events risks may be
used to design future intervention studies on start and
withdrawal of secondary prevention in these young patients,
as the current prescription of these drugs is based onextrapolated findings from stroke trials in which young
patients have been underrepresented or excluded.
In conclusion, ODYSSEY is designed to prospectively
determine prognosis after a young stroke and get more
insight in etiology of patients with a TIA, ischemic stroke
and intracerebral hemorrhage in patients aged 18 through
49 years old in a large sample size.
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